Innovative Science, breakthrough technology, first-in-class treatments. These are the foundations on which Rgenix is built. They are at the core of everything we do. Our top-tier team is focused on developing cutting-edge medicines with the goal of curing cancers of high unmet need—and ultimately saving lives.
Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.
Using a discovery platform developed by Rgenix’s founding scientists at Rockefeller University, and now exclusively licensed to Rgenix, we have discovered several novel cancer targets that drive tumor growth and cancer progression. These targets regulate key components of the tumor micro-environment including immune cells and cancer metabolism pathways.
Our Discovery Platform
Our discovery platform—which can be applied to virtually any tumor type—has yielded novel therapeutic targets for several high unmet need cancer types to date. We aim to develop effective therapies against these targets that will provide durable and meaningful responses for cancer patients that lack effective therapies.
Our lead drug candidate (RGX-104) is a small molecule immunotherapy that targets the immune system to treat cancer progression.
RGX-104 has obtained FDA Orphan Drug Designation in several solid tumor types of high unmet need and is currently being evaluated in a Phase 1b/2 clinical trial in lung cancer patients.
Our company brings together distinguished scientific founders, a seasoned board, and a leadership team comprised of experienced drug developers.